Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 7, 2026

Pathological insights of human CD34+ hematopoietic stem cell-engrafted NSG mice: Implications for the safety assessment of cancer immunotherapy drugs.

View Full Paper
Ask AI
Bookmark
Share

Authors

AGAnna Maria GiustiJSJohannes Atta SamSCSara Colombetti

Discussion

Loading...

Member takes

Overview

Evaluates safety assessments of cancer immunotherapy drugs using human CD34+ HSC-engrafted mice, indicating significant model-specific pathology issues.

Key Points

  • The aim is to explore pathological changes in human CD34+ HSC-engrafted NSG mice to improve safety assessments for cancer immunotherapy drugs.
  • Characterized engraftment kinetics and histopathology across various timepoints.
  • Utilized flow cytometry and immunohistochemistry for immune cell population analysis.
  • Examined the effects of immuno-oncology compounds on model-specific background lesions.
  • Observed prevalence of B cells early, shifting to T cell predominance at later stages.
  • Identified spontaneous granulomatous lesions in multiple organs, increasing with time and exacerbated by treatments.
  • Detected bone marrow necrosis resembling ischemic lesions, particularly after immune stimulation.

Cite This Study

Giusti et al. (2026) studied this question.

synapsesocial.com/papers/69abc1d75af8044f7a4eadfbhttps://doi.org/10.1177/03009858261423132
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Humanized Immune Mouse Models: Emerging Applications for Cancer Immunotherapy2025 · 1 citations
  2. 2Abstract 112: The NSG-Flt3KO; Tg(hFLT3LG); hIL15 mouse strain improves engraftment of innate immune cells post-CD34+ humanization2024 · 1 citations
  3. 3Characterization of the Xeno-GVHD Response Generated by Lung Cancer Patient PBMCs in NSG-SGM3 Mice2024
  4. 4Abstract 3385: Humanized mouse models 2.0 - Improved preclinical evaluation of novel immune cell therapies, check point inhibitors, and immune cell engagers by excluding false positive or negative results2026
  5. 5Xenotransplantation of Human Hematopoietic Stem Cells into NBSGW Mice: A Basic Model for Preclinical Development of Gene Therapy Approaches2024